Chao Tong1, Hui Liu1, Rihui Chen1, Fengting Zhu2. 1. Department of Interventional Radiology, Central South University, Xiangya School of Medicine Affiliated Haikou Hospital Haikou, Hainan Province, China. 2. Department of Oncology, Hainan Hospital of Traditional Chinese Medicine Haikou, Hainan Province, China.
Abstract
OBJECTIVE: To investigate the efficacy of transcatheter arterial chemoembolization (TACE) combined with thalidomide-mediated adjuvant therapy on the expression levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in hepatocellular carcinoma (HCC) patients. METHODS: A prospective study was designed, by which 134 HCC patients from our hospital who underwent treatment were selected and randomly divided into an observation group and a control group, 67 participants per group. The control group was administered hepatic TACE, while the observation group was given TACE in combination with thalidomide. The total disease control rate (DCR) and the rate of adverse effects were analyzed and compared between the two groups of patients. The expression levels of CD3+, CD4+, CD8+, CD4+/CD8+, VEGF, VEGFA, and bFGF were measured between the two groups before and after treatment. The overall survival rate of the two groups were also compared after a follow-up for 3 years. RESULTS: The rate of adverse effects and DCR in the control group were 44.78% and 61.19%, respectively, whereas these rates were 22.39% and 89.55% in the observation group, respectively. Of note, the differences in terms of the rate of adverse effects and DCR were statistically significant between the two groups (P<0.05). Before treatment, no significant difference was shown regarding the expression levels of CD3+, CD4+, CD8+, CD4+/CD8+, VEGF, VEGFA, and bFGF between the two groups (P>0.05). After treatment, the expression levels of CD3+, CD4+, and CD4+/CD8+ were significantly upregulated in the two groups, while the levels of CD8+, VEGF, VEGFA, and bFGF were considerably downregulated (P<0.05). In addition, compared with the control group, the expression levels of CD3+, CD4+, and CD4+/CD8+ were significantly higher, whereas the levels of CD8+, VEGF, VEGFA, and bFGF were notably lower in the observation group (P<0.05). After the follow-up for 3 years, the overall survival rate of the observation group was significantly higher in comparison to the control group (P<0.05). CONCLUSION:TACE in combination with thalidomide-mediated adjuvant treatment has revealed a promising clinical outcome on HCC patients by downregulating the levels of VEGF and bFGF. AJTR
RCT Entities:
OBJECTIVE: To investigate the efficacy of transcatheter arterial chemoembolization (TACE) combined with thalidomide-mediated adjuvant therapy on the expression levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in hepatocellular carcinoma (HCC) patients. METHODS: A prospective study was designed, by which 134 HCC patients from our hospital who underwent treatment were selected and randomly divided into an observation group and a control group, 67 participants per group. The control group was administered hepatic TACE, while the observation group was given TACE in combination with thalidomide. The total disease control rate (DCR) and the rate of adverse effects were analyzed and compared between the two groups of patients. The expression levels of CD3+, CD4+, CD8+, CD4+/CD8+, VEGF, VEGFA, and bFGF were measured between the two groups before and after treatment. The overall survival rate of the two groups were also compared after a follow-up for 3 years. RESULTS: The rate of adverse effects and DCR in the control group were 44.78% and 61.19%, respectively, whereas these rates were 22.39% and 89.55% in the observation group, respectively. Of note, the differences in terms of the rate of adverse effects and DCR were statistically significant between the two groups (P<0.05). Before treatment, no significant difference was shown regarding the expression levels of CD3+, CD4+, CD8+, CD4+/CD8+, VEGF, VEGFA, and bFGF between the two groups (P>0.05). After treatment, the expression levels of CD3+, CD4+, and CD4+/CD8+ were significantly upregulated in the two groups, while the levels of CD8+, VEGF, VEGFA, and bFGF were considerably downregulated (P<0.05). In addition, compared with the control group, the expression levels of CD3+, CD4+, and CD4+/CD8+ were significantly higher, whereas the levels of CD8+, VEGF, VEGFA, and bFGF were notably lower in the observation group (P<0.05). After the follow-up for 3 years, the overall survival rate of the observation group was significantly higher in comparison to the control group (P<0.05). CONCLUSION:TACE in combination with thalidomide-mediated adjuvant treatment has revealed a promising clinical outcome on HCC patients by downregulating the levels of VEGF and bFGF. AJTR
Authors: Jennifer Wu; Jennifer Ng; Paul J Christos; Alec S Goldenberg; Joseph Sparano; Max W Sung; Howard S Hochster; Franco M Muggia Journal: Oncologist Date: 2014-10-31
Authors: Shuo Zhang; Decai Tang; Wenhua Zang; Gang Yin; Jianguo Dai; Y U Sun; Zhijian Yang; Robert M Hoffman; Xiuxia Guo Journal: Anticancer Res Date: 2017-02 Impact factor: 2.480